Close Menu

Abbott

Following a partial response to Abbott's request to audit its books, Alere said it is confident the transaction will be completed.

The GenomeWeb Index fell 1 percent in April, outperforming the Nasdaq, but falling significantly short of the performance of the Nasdaq Biotech Index.

Alere also said that some of its creditors have agreed to waive defaults arising from its delay in filing its 2015 earnings report, though others have already filed default notices.

The company said its financial plan contemplates the acquisition of both St. Jude and Alere, which is under investigation for its foreign business practices.

Abbott reported Diagnostics sales of $1.12 billion, up 2 percent on a reported basis and 7 percent excluding foreign currency effects.

The companion test will let doctors identify the best treatment for CLL patients with 17p deletions, a subset that has historically lacked therapeutic options.

The test, which was previously approved for CLL prognosis, is now cleared for use in identifying patients who may benefit from AbbVie and Genentech's Venclexta.

Abbott Molecular has been building a PCR-based system from the ground up and plans to sell it in parallel with the m2000, eventually replacing that system.

The GenomeWeb Index rose more than 6 percent in March, in line with the Dow and the Nasdaq, and significantly outperforming the Nasdaq Biotech Index.

The company notified the Securities and Exchange Commission of the subpoena and noted that it will delay filing its annual earnings for 2015. 

Pages

The Guardian reports that visa costs could prevent scientists and others from coming to the UK.

The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.

Nature News says some preprint repositories may close down due to a lack of funds to cover costs.

In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.